{"id":"NCT00435812","sponsor":"Dynavax Technologies Corporation","briefTitle":"Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine","officialTitle":"A Phase III Safety and Efficacy Study to Compare Immune Responses Following Injection With Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B®","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2008-02","completion":"2008-03","firstPosted":"2007-02-15","resultsPosted":"2018-02-13","lastUpdate":"2019-03-20"},"enrollment":2428,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis B"],"interventions":[{"type":"BIOLOGICAL","name":"HEPLISAV and/or Placebo","otherNames":["HEPLISAV","Hepatitis B vaccine (recombinant), adjuvanted"]},{"type":"BIOLOGICAL","name":"Engerix-B","otherNames":["Hepatitis B vaccine (recombinant)"]}],"arms":[{"label":"HEPLISAV and/or Placebo","type":"EXPERIMENTAL"},{"label":"Engerix-B","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to find out if a new investigational hepatitis B virus vaccine, HEPLISAV™, is safe and effective compared with Engerix-B® vaccine in subjects 11-55 years old. The primary hypothesis is that the seroprotective immune response of HEPLISAV™ is at least as good as that of Engerix-B®.","primaryOutcome":{"measure":"Percentage of Subjects With Seroprotective Immune Response","timeFrame":"Week 12 for HEPLISAV and Week 28 for Engerix-B","effectByArm":[{"arm":"HEPLISAV and/or Placebo","deltaMin":95.1,"sd":null},{"arm":"Engerix-B","deltaMin":81.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":18,"countries":["Canada","Germany"]},"refs":{"pmids":[],"seeAlso":["http://www.dynavax.com"]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":1821},"commonTop":["Nasopharyngitis","Headache","Back pain"]}}